Conjugating Prussian Blue Nanoparticles Onto antigen-specific T Cells As a Combined Nanoimmunotherapy

Burga, Rachel A.; Patel, Shabnum; Bollard, Catherine M.; Cruz, Conrad Russell Y.; Fernandes, Rohan

doi:10.2217/nnm-2016-0160

Cited by 55 publications

(28 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously discussed, PTT as a standalone therapy faces risk of recurrence and is not suitable for treating disseminated metastatic disease. Combining PTT with immunotherapy may prevent tumor recurrence and inhibit metastases . Immunotherapy is a rapidly emerging, promising technique in which the host immune system is stimulated to recognize and kill cancer cells that have adapted various means of avoiding immune recognition .…”

Section: Combining Photothermal Therapy With Immunotherapy For Prolonmentioning

confidence: 99%

“…Immunotherapy counteracts these mechanisms by delivering tumor‐specific T cells, immune checkpoint inhibitors (antibodies against CTLA‐4 or PD‐L1), or CpG oligodeoxynucleotides (which are recognized by toll‐like receptor 9 (TLR9) on B cells and plasmacytoid DCs to stimulate an immune response). Each of these strategies has been evaluated in combination with PTT (mediated by both AuNPs and non‐AuNPs), and the results indicate that dual PTT/immunotherapy is advantageous to either therapy alone …”

Section: Combining Photothermal Therapy With Immunotherapy For Prolonmentioning

confidence: 99%

“…Combining PTT with immunotherapy may prevent tumor recurrence and inhibit metastases. 2,55,[72][73][74][75][76][77] Immunotherapy is a rapidly emerging, promising technique in which the host immune system is stimulated to recognize and kill cancer cells that have adapted various means of avoiding immune recognition. 78 One way cancer cells avoid recognition is by secreting cytokines such as IL-10 that suppress DC maturation (mature DCs capture tumor antigens and present them to T cells for activation).…”

Section: Combining Photothermal Therapy With Immunotherapy For Prolonmentioning

confidence: 99%

See 2 more Smart Citations

Gold nanoparticle‐mediated photothermal therapy: applications and opportunities for multimodal cancer treatment

Riley

Day

2017

WIREs Nanomed Nanobiotechnol

598

454

View full text Add to dashboard Cite

Photothermal therapy (PTT), in which nanoparticles embedded within tumors generate heat in response to exogenously applied laser light, has been well documented as an independent strategy for highly selective cancer treatment. Gold-based nanoparticles are the main mediators of PTT because they offer: (1) biocompatibility, (2) small diameters that enable tumor penetration upon systemic delivery, (3) simple gold-thiol bioconjugation chemistry for the attachment of desired molecules, (4) efficient light-to-heat conversion, and (5) the ability to be tuned to absorb near-infrared light, which penetrates tissue more deeply than other wavelengths of light. In addition to acting as a standalone therapy, gold nanoparticle-mediated PTT has recently been evaluated in combination with other therapies, such as chemotherapy, gene regulation, and immunotherapy, for enhanced anti-tumor effects. When delivered independently, the therapeutic success of molecular agents is hindered by premature degradation, insufficient tumor delivery, and off-target toxicity. PTT can overcome these limitations by enhancing tumor- or cell-specific delivery of these agents or by sensitizing cancer cells to these additional therapies. All together, these benefits can enhance the therapeutic success of both PTT and the secondary treatment while lowering the required doses of the individual agents, leading to fewer off-target effects. Given the benefits of combining gold nanoparticle-mediated PTT with other treatment strategies, many exciting opportunities for multimodal cancer treatment are emerging that will ultimately lead to improved patient outcomes.

show abstract

Section: Combining Photothermal Therapy With Immunotherapy For Prolonmentioning

confidence: 99%

Section: Combining Photothermal Therapy With Immunotherapy For Prolonmentioning

confidence: 99%

Section: Combining Photothermal Therapy With Immunotherapy For Prolonmentioning

confidence: 99%

See 1 more Smart Citation

Gold nanoparticle‐mediated photothermal therapy: applications and opportunities for multimodal cancer treatment

Riley

Day

2017

WIREs Nanomed Nanobiotechnol

598

454

View full text Add to dashboard Cite

show abstract

“…This strategy is currently in commercial/clinical translation by Torque Pharmaceuticals. In a similar vein, Prussian blue nanoparticles (PBNPs) that exhibit photothermal responsiveness were conjugated to Epstein-Barr virus (EBV)-specific CD8 + T-cells, to enable homing of these photothermal agents to EBV-associated tumor malignancies [266]. Wayteck et al designed a reversible coupling strategy linking siRNA-carrying liposomes to the surface of CD8 + T cells via disulfide bonds [267].…”

Section: Engineering Safer Systemic Immunotherapiesmentioning

confidence: 99%

Delivering safer immunotherapies for cancer

Milling

Zhang

Irvine

2017

Advanced Drug Delivery Reviews

245

168

View full text Add to dashboard Cite

Cancer immunotherapy is now a powerful clinical reality, with a steady progression of new drug approvals and a massive pipeline of additional treatments in clinical and preclinical development. However, modulation of the immune system can be a double-edged sword: Drugs that activate immune effectors are prone to serious non-specific systemic inflammation and autoimmune side effects. Drug delivery technologies have an important role to play in harnessing the power of immune therapeutics while avoiding on-target/off-tumor toxicities. Here we review mechanisms of toxicity for clinically-relevant immunotherapeutics, and discuss approaches based in drug delivery technology to enhance the safety and potency of these treatments. These include strategies to merge drug delivery with adoptive cellular therapies, targeting immunotherapies to tumors or select immune cells, and localizing therapeutics intratumorally. Rational design employing lessons learned from the drug delivery and nanomedicine fields has the potential to facilitate immunotherapy reaching its full potential.

show abstract

“…To answer these questions, we utilize Prussian blue nanoparticles (PBNPs) for PTT (PBNP‐PTT) ( Figure A; Figure S1, Supporting Information). PBNPs are biodegradable, the United States Food and Drug Administration (FDA)‐approved nanoparticles that we have previously used for PTT of tumors, both alone and in combination with chemotherapy and immunotherapies . Specifically, we administer varying thermal doses of PBNP‐PTT to tumor cells in vitro and in vivo by varying the PBNP concentrations and the laser power.…”

mentioning

confidence: 99%

Photothermal Therapy Generates a Thermal Window of Immunogenic Cell Death in Neuroblastoma

Sweeney

Cano‐Mejia

Fernandes

2018

Small

Self Cite

185

163

View full text Add to dashboard Cite

A thermal "window" of immunogenic cell death (ICD) elicited by nanoparticle-based photothermal therapy (PTT) in an animal model of neuroblastoma is described. In studies using Prussian blue nanoparticles to administer photothermal therapy (PBNP-PTT) to established localized tumors in the neuroblastoma model, it is observed that PBNP-PTT conforms to the "more is better" paradigm, wherein higher doses of PBNP-PTT generates higher cell/local heating and thereby more cell death, and consequently improved animal survival. However, in vitro analysis of the biochemical correlates of ICD (ATP, high-motility group box 1, and calreticulin) elicited by PBNP-PTT demonstrates that PBNP-PTT triggers a thermal window of ICD. ICD markers are highly expressed within an optimal temperature (thermal dose) window of PBNP-PTT (63.3-66.4 °C) as compared with higher (83.0-83.5 °C) and lower PBNP-PTT (50.7-52.7 °C) temperatures, which both yield lower expression. Subsequent vaccination studies in the neuroblastoma model confirm the in vitro findings, wherein PBNP-PTT administered within the optimal temperature window results in long-term survival (33.3% at 100 d) compared with PBNP-PTT administered within the higher (0%) and lower (20%) temperature ranges, and controls (0%). The findings demonstrate a tunable immune response to heat generated by PBNP-PTT, which should be critically engaged in the administration of PTT for maximizing its therapeutic benefits.

show abstract

Conjugating Prussian Blue Nanoparticles Onto antigen-specific T Cells As a Combined Nanoimmunotherapy

Abstract: This study highlights the potential of our CTL:PBNPs nanoimmunotherapy as a novel therapeutic for treating virus-associated malignancies such as EBV+ cancers.

Cited by 55 publications

References 25 publications

Gold nanoparticle‐mediated photothermal therapy: applications and opportunities for multimodal cancer treatment

Gold nanoparticle‐mediated photothermal therapy: applications and opportunities for multimodal cancer treatment

Delivering safer immunotherapies for cancer

Photothermal Therapy Generates a Thermal Window of Immunogenic Cell Death in Neuroblastoma

Contact Info

Product

Resources

About